Stay updated with breaking news from Structurally Targeted Allosteric Regulators. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BETHESDA, Md., May 03, 2023 -- Gain Therapeutics, Inc. , a biotechnology company leading the discovery and development of allosteric small molecule therapies, today announced that Innosuisse, the... | May 3, 2023
Parkinson’s disease has been immensely challenging for biotech companies. A high rate of late-stage attrition in trials has led to a lack of approved therapies for the disease.
Compounds reverse the neurodegenerative process observed in a Parkinson’s disease in vivo model Compounds are novel allosteric regulators that bind, stabilize and restore activity of mutated GCase Compounds decrease both phosphorylated and aggregated α -synuclein levels in vitro and in vivo BETHESDA, Md., May 03, 2021 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”), a biotechnology company focused on redefining drug discovery by using super-computational methods to target allosteric binding sites and guide enzymes back to their proper shape, today announced new pr...